Lung cancer patients with anaplastic lymphoma kinase rearrangement lose affiliation with labor market at diagnosis

References

• Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Rasmussen TR, Jakobsen E, Rasmussen C et al. Dansk Lunge Cancer Register Årsrapport 2021. Aarhus, Denmark: Regionernes Kliniske Kvalitetsudviklingsprogram; 2021.
   Google Scholar
• Howlader N, Forjaz G, Mooradian MJ et al. The effect of advances in lung-cancer treatment on population mortality. N. Engl. J. Med. 2020;383(7):640–649.
   PubMed Web of Science ®Google Scholar
• Rebuzzi SE, Zullo L, Rossi G et al. Novel emerging molecular targets in non-small-cell lung cancer. Int. J. Mol. Sci. 2021;22(5):2625.
   PubMed Web of Science ®Google Scholar
• Ricciardi S, Tomao S, de Marinis F. Toxicity of targeted therapy in non–small-cell lung cancer management. Clinical Lung Cancer 2009;10(1):28–35.
   PubMed Web of Science ®Google Scholar
• de Boer AG, Torp S, Popa A et al. Long-term work retention after treatment for cancer: a systematic review and meta-analysis. J. Cancer Surviv. 2020;14(2):135–150.
   PubMed Web of Science ®Google Scholar
• Vayr F, Savall F, Bigay-Game L et al. Lung cancer survivors and employment: a systematic review. Lung Cancer 2019;131:31–39.
   PubMed Web of Science ®Google Scholar
• Butow P, Laidsaar-Powell R, Konings S et al. Return to work after a cancer diagnosis: a meta-review of reviews and a meta-synthesis of recent qualitative studies. J. Cancer Surviv. 2020;14(2):114–134.
   PubMed Web of Science ®Google Scholar
• Paltrinieri S, Fugazzaro S, Bertozzi L et al. Return to work in European cancer survivors: a systematic review. Support. Care Cancer 2018;26(9):2983–2994.
   PubMed Web of Science ®Google Scholar
• Rashid H, Eichler M, Hechtner M et al. Returning to work in lung cancer survivors-a multi-center cross-sectional study in Germany. Support. Care Cancer 2021;29(7):3753–3765.
   PubMed Web of Science ®Google Scholar
• Rasmussen TR, Jakobsen E, Rasmussen C et al. Dansk Lunge Cancer Register Årsrapport 2015. Hedeager, DK-8200, Aarhus, Denmark: Regionernes Kliniske Kvalitetsudviklingsprogram; Regionshuset Aarhus; 2021 2016.
   Google Scholar
• Planchard D, Popat S, Kerr K et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2018;29(Suppl. 4):iv192–iv237.
   PubMed Web of Science ®Google Scholar
• Postmus PE, Kerr KM, Oudkerk M et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2017;28(Suppl. 4):iv1–iv21.
   PubMedGoogle Scholar
• Lindbohm ML, Kuosma E, Taskila T et al. Cancer as the cause of changes in work situation (a NOCWO study). Psychooncology 2011;20(8):805–812.
   PubMed Web of Science ®Google Scholar
• Paraponaris A, Teyssier LS, Ventelou B. Job tenure and self-reported workplace discrimination for cancer survivors 2 years after diagnosis: does employment legislation matter? Health Policy 2010;98(2–3):144–155.
   PubMed Web of Science ®Google Scholar
• Lauppe R, Nilsson FOL, Fues Wahl H et al. Use of ALK-tyrosine kinase inhibitors (ALK TKI) in clinical practice, overall survival, and treatment duration - a Swedish nationwide retrospective study. Acta Oncol. 2022; 61(11):1–8.
   PubMed Web of Science ®Google Scholar
• Hansen KH, Johansen JS, Urbanska EM et al. Clinical outcomes of ALK+ non-small-cell lung cancer in Denmark. Acta Oncol. 2023;62(12):1775–1783.
   PubMed Web of Science ®Google Scholar
• Sakamoto T, Matsubara T, Takahama T et al. Biomarker testing in patients with unresectable advanced or recurrent non-small-cell lung cancer. JAMA Netw Open. 2023;6(12):e2347700.
   PubMed Web of Science ®Google Scholar
• Schmid S, Cheng S, Chotai S et al. Real-world treatment sequencing, toxicities, health utilities, and survival outcomes in patients with advanced ALK-rearranged non-small-cell lung cancer. Clin. Lung Cancer 2023;24(1):40–50.
   PubMed Web of Science ®Google Scholar
• Marinelli D, Siringo M, Metro G et al. Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease. Drugs Context 2022;11:2022-3-1.
   PubMedGoogle Scholar
• Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448(7153):561–566.
   PubMed Web of Science ®Google Scholar
• Skov BG, Clementsen P, Larsen KR et al. The prevalence of ALK rearrangement in pulmonary adenocarcinomas in an unselected Caucasian population from a defined catchment area: impact of smoking. Histopathology 2017;70(6):889–895.
   PubMed Web of Science ®Google Scholar
• Pacheco JM, Gao D, Smith D et al. Natural history and factors associated with overall survival in stage IV ALK-rearranged non-small-cell lung cancer. J. Thorac. Oncol. 2019;14(4):691–700.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim D-W et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 2014;371(23):2167–2177.
   PubMed Web of Science ®Google Scholar
• Harris PA, Taylor R, Minor BL et al. The REDCap consortium: building an international community of software platform partners. J. Biomed. Inform. 2019;95:103208.
   PubMed Web of Science ®Google Scholar
• Erichsen R, Lash TL, Hamilton-Dutoit SJ et al. Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin. Epidemiol. 2010;2:51–56.
   PubMedGoogle Scholar
• Leuven E, Sianesi B. PSMATCH2: stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing. [ Statistical Software Components]. http://EconPapers.repec.org/RePEc:boc:bocode:s432001 2003.
   Google Scholar
• Hjollund NH, Larsen FB, Andersen JH. Register-based follow-up of social benefits and other transfer payments: accuracy and degree of completeness in a Danish interdepartmental administrative database compared with a population-based survey. Scandin. J. Public Health 2007;35(5):497–502.
   PubMed Web of Science ®Google Scholar
• Britschgi C, Addeo A, Rechsteiner M et al. Real-world treatment patterns and survival outcome in advanced anaplastic lymphoma kinase (ALK) rearranged non-small-cell lung cancer patients. Front. Oncol. 2020;10:1299.
   PubMed Web of Science ®Google Scholar
• Gibson AJW, Box A, Dean ML et al. Retrospective real-world outcomes for patients with ALK-rearranged lung cancer receiving ALK receptor tyrosine kinase inhibitors. JTO Clin. Res. Rep. 2021;2(4):100157.
   PubMedGoogle Scholar
• Eide IJZ, Nilssen Y, Stensland EM et al. Real-world data on EGFR and ALK testing and TKI usage in Norway-A nation-wide population study. Cancers (Basel) 2023;15(5):1505.
   PubMed Web of Science ®Google Scholar
• Pacheco JM, Camidge DR. Is long-term survival possible for patients with stage IV ALK+ non-small-cell lung cancer? Exp. Rev. Respir. Med. 2019;13(5):399–401.
   PubMed Web of Science ®Google Scholar
• Roelen CA, Koopmans PC, Groothoff JW et al. Sickness absence and full return to work after cancer: 2-year follow-up of register data for different cancer sites. Psychooncology 2011;20(9):1001–1006.
   PubMed Web of Science ®Google Scholar
• Yang ZY, Lai CH, Ho CL et al. Epidemiological study of return to work and mortality in lung cancer survivors. Int. J. Environ. Res. Public Health 2021;19(1):309.
   PubMed Web of Science ®Google Scholar
• Lai-Kwon J, Heynemann S, Flore J et al. Living with and beyond metastatic non-small-cell lung cancer: the survivorship experience for people treated with immunotherapy or targeted therapy. J. Cancer Surviv. 2021;15(3):392–397.
   PubMed Web of Science ®Google Scholar
• Lin HM, Pan X, Biller A et al. Humanistic burden of living with anaplastic lymphoma kinase-positive non-small-cell lung cancer: findings from the ALKConnect patient insight network and research platform. Lung Cancer Manag. 2020;10(1):Lmt42.
   PubMed Web of Science ®Google Scholar